Ronak Lakhia1. 1. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Abstract
PURPOSE OF REVIEW: Metabolic reprogramming is a prominent feature of cyst epithelial cells in autosomal dominant polycystic kidney disease (ADPKD). Peroxisome proliferator activated receptor alpha (PPARα) is a transcription factor that regulates many aspects of cellular metabolism. The purpose of this review is to understand the role of PPARα in ADPKD. RECENT FINDINGS: PPARα expression is reduced in ADPKD kidneys of mice and humans. This downregulation is in part secondary to microRNA mediated translational repression and leads to impairment of fatty acid metabolism. Genetic studies demonstrate that deletion of Pparα aggravates cyst growth in a slowly progressive mouse model of ADPKD. Recent studies also show that administration of Pparα agonists ameliorates cyst burden in mice. SUMMARY: Abnormal reduction of PPARα affects cellular metabolism in ADPKD. Pparα is a modulator of cyst progression in mouse models of ADPKD. These studies establish PPARα as an exciting new drug target for the treatment of individuals with ADPKD.
PURPOSE OF REVIEW: Metabolic reprogramming is a prominent feature of cyst epithelial cells in autosomal dominant polycystic kidney disease (ADPKD). Peroxisome proliferator activated receptor alpha (PPARα) is a transcription factor that regulates many aspects of cellular metabolism. The purpose of this review is to understand the role of PPARα in ADPKD. RECENT FINDINGS:PPARα expression is reduced in ADPKD kidneys of mice and humans. This downregulation is in part secondary to microRNA mediated translational repression and leads to impairment of fatty acid metabolism. Genetic studies demonstrate that deletion of Pparα aggravates cyst growth in a slowly progressive mouse model of ADPKD. Recent studies also show that administration of Pparα agonists ameliorates cyst burden in mice. SUMMARY: Abnormal reduction of PPARα affects cellular metabolism in ADPKD. Pparα is a modulator of cyst progression in mouse models of ADPKD. These studies establish PPARα as an exciting new drug target for the treatment of individuals with ADPKD.
Authors: Ki Wung Chung; Eun Kyeong Lee; Mi Kyung Lee; Goo Taeg Oh; Byung Pal Yu; Hae Young Chung Journal: J Am Soc Nephrol Date: 2018-02-12 Impact factor: 10.121
Authors: Katharina Hopp; Christopher J Ward; Cynthia J Hommerding; Samih H Nasr; Han-Fang Tuan; Vladimir G Gainullin; Sandro Rossetti; Vicente E Torres; Peter C Harris Journal: J Clin Invest Date: 2012-10-15 Impact factor: 14.808
Authors: Thomas R Flint; Tobias Janowitz; Claire M Connell; Edward W Roberts; Alice E Denton; Anthony P Coll; Duncan I Jodrell; Douglas T Fearon Journal: Cell Metab Date: 2016-11-08 Impact factor: 27.287
Authors: Edmund C Lee; Tania Valencia; Charles Allerson; Annelie Schairer; Andrea Flaten; Matanel Yheskel; Kara Kersjes; Jian Li; Sole Gatto; Mandeep Takhar; Steven Lockton; Adam Pavlicek; Michael Kim; Tiffany Chu; Randy Soriano; Scott Davis; John R Androsavich; Salma Sarwary; Tate Owen; Julia Kaplan; Kai Liu; Graham Jang; Steven Neben; Philip Bentley; Timothy Wright; Vishal Patel Journal: Nat Commun Date: 2019-09-12 Impact factor: 14.919